Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
N-Acetylcysteine increases corneal endothelial cell survival in a mouse model of Fuchs endothelial corneal dystrophy.
[]
The
present
study
evaluated
survival
effects
of
N-
acetylcysteine
(
NAC
)
on
cultured
corneal
endothelial
cells
exposed
to
oxidative
and
endoplasmic
reticulum
(
ER
)
stress
and
in
a
mouse
model
of
early
-onset
Fuchs
endothelial
corneal
dystrophy
(
FECD
)
.
Cultured
bovine
corneal
endothelial
cell
viability
against
oxidative
and
ER
stress
was
determined
by
CellTiter-Glo
(
®
)
luminescent
reagent
.
Two
-
month
-old
homozygous
knock-
in
Col
8
a
2
(
L
450
W
/
L
450
W
)
mutant
(
L
450
W
)
and
C
5
7
/
Bl
6
wild-
type
(
WT
)
animals
were
divided
into
two
groups
of
15
mice
.
Group
I
received
7
Â
mg
/
mL
NAC
in
drinking
water
and
Group
II
received
control
water
for
7
months
.
Endothelial
cell
density
and
morphology
were
evaluated
with
confocal
microscopy
.
Antioxidant
gene
(
iNos
)
and
ER
stress
/
unfolded
protein
response
gene
(
Grp
78
and
Chop
)
mRNA
levels
and
protein
expression
were
measured
in
corneal
endothelium
by
real
time
PCR
and
Western
blotting
.
Cell
viability
of
H
2
O
2
and
thapsigargin
exposed
cells
pre-treated
with
NAC
was
significantly
increased
compared
to
untreated
controls
(
p
Â
<
Â
0
.
01
)
.
Corneal
endothelial
cell
density
(
CD
)
was
higher
(
p
Â
=
Â
0
.
001
)
and
percent
polymegathism
was
lower
(
p
Â
=
Â
0
.
04
)
in
NAC
treated
L
450
W
mice
than
in
untreated
L
450
W
mice
.
NAC
treated
L
450
W
endothelium
showed
significant
upregulation
of
iNos
,
whereas
Grp
78
and
Chop
were
downregulated
compared
to
untreated
L
450
W
endothelium
by
real
time
PCR
and
Western
blotting
.
NAC
increases
survival
in
cultured
corneal
endothelial
cells
exposed
against
ER
and
oxidative
stress
.
Systemic
NAC
ingestion
increases
corneal
endothelial
cell
survival
which
is
associated
with
increased
antioxidant
and
decreased
ER
stress
markers
in
a
mouse
model
of
early
-onset
FECD
.
Our
study
presents
in
Â
vivo
evidence
of
a
novel
potential
medical
treatment
for
FECD
.